Solid state transformations in consequence of electrospraying--a novel polymorphic form of piroxicam.

The aim of the research was to verify that electrospraying of piroxicam yielded a new polymorphic form of this drug. In the experiments, piroxicam was dissolved in chloroform and the solution was atomised electrostatically. Subsequently, the charged droplets were neutralised and dried. The solid drug particles were collected and analysed by scanning electron microscopy, X-ray diffraction, differential scanning calorimetry, high performance liquid chromatography, and infrared and Raman spectroscopy. The X-ray diffractogram measured for the electrosprayed piroxicam particles did not match with any of the known piroxicam crystal structures (Cambridge Crystallographic Data Centre). The variable temperature X-ray diffraction showed that the structure recrystallised completely into piroxicam polymorphic formI during heating. No degradation products or solvate removal was detected by high performance liquid chromatography and thermal analysis. The infrared and Raman spectra of the electrosprayed piroxicam were compared to those of formI, and some notable differences in the peak positions, shapes and intensities were detected. The results indicate that electrospraying leads to piroxicam crystallisation in a currently unknown polymorphic form.

[1]  Bernhardt L Trout,et al.  Production and characterization of carbamazepine nanocrystals by electrospraying for continuous pharmaceutical manufacturing. , 2011, Journal of pharmaceutical sciences.

[2]  M. Sarkar,et al.  Spectroscopic studies of microenvironment dictated structural forms of piroxicam and meloxicam , 2002 .

[3]  A. Bailey,et al.  ELECTROSTATIC SPRAYING OF LIQUIDS , 1988 .

[4]  R. N. Brogden,et al.  Piroxicam: A Review of its Pharmacological Properties and Therapeutic Efficacy , 1981, Drugs.

[5]  J. Rantanen,et al.  Polymorphic form of piroxicam influences the performance of amorphous material prepared by ball-milling. , 2012, International journal of pharmaceutics.

[6]  Michael J Cima,et al.  High-throughput crystallization: polymorphs, salts, co-crystals and solvates of pharmaceutical solids. , 2004, Advanced drug delivery reviews.

[7]  A. Whittington,et al.  Melting point depression of Piroxicam in carbon dioxide + co-solvent mixtures and inclusion complex formation with β-cyclodextrin , 2012 .

[8]  S. M. Andrade,et al.  Hydrogen bonding effects in the photophysics of a drug, Piroxicam, in homogeneous media and dioxane–water mixtures , 1999 .

[9]  F. Vrečer,et al.  Characterization of piroxicam crystal modifications. , 2003, International journal of pharmaceutics.

[10]  A. Nokhodchi,et al.  Effect of glucosamine HCl on dissolution and solid state behaviours of piroxicam upon milling. , 2013, Colloids and surfaces. B, Biointerfaces.

[11]  Complementing high-throughput X-ray powder diffraction data with quantum-chemical calculations: Application to piroxicam form III. , 2012, Journal of pharmaceutical sciences.

[12]  A. D'Ursi,et al.  Piroxicam loaded alginate beads obtained by prilling/microwave tandem technique: morphology and drug release. , 2012, Carbohydrate polymers.

[13]  M. Janik,et al.  Influence of solvent effect on polymorphism of 4-hydroxy-2-methyl-N-2-pyridyl-2H-1,2-benzothiazine-3-carboxamide-1, 1-dioxide (piroxicam) , 1991 .

[14]  John A. Lowe,et al.  A guide to drug discovery: The role of the medicinal chemist in drug discovery — then and now , 2004, Nature Reviews Drug Discovery.

[15]  P. Taddei,et al.  Influence of environment on piroxicam polymorphism: vibrational spectroscopic study. , 2001, Biopolymers.

[16]  Kenneth I. Hardcastle,et al.  Cocrystals of Piroxicam with Carboxylic Acids , 2007 .

[17]  M. Nyström,et al.  Fabrication and characterization of drug particles produced by electrospraying into reduced pressure , 2010 .

[18]  N. Sandler,et al.  Processing of pharmaceutical materials by electrospraying under reduced pressure , 2015, Drug development and industrial pharmacy.

[19]  Chick C. Wilson,et al.  Tautomerisation and polymorphism in molecular complexes of piroxicam with mono-substituted benzoic acids , 2012 .

[20]  E. Höhne,et al.  X-ray studies on piroxicam modifications. , 1988, Die Pharmazie.

[21]  J. Bordner,et al.  Deuterium isotope effects on carbon-13 NMR shifts and the tautomeric equilibrium in N-substituted pyridyl derivatives of piroxicam , 1989 .

[22]  G. Reck,et al.  Prediction and establishment of a new crystalline piroxicam modification. , 1990, Die Pharmazie.

[23]  R. Pansu,et al.  The Influence of Water on the Photophysical and Photochemical Properties of Piroxicam in AOT/iso‐octane/Water Reversed Micelles , 2000, Photochemistry and photobiology.

[24]  J. Heinämäki,et al.  Water-mediated solid-state transformation of a polymorphic drug during aqueous-based drug-layer coating of pellets. , 2013, International journal of pharmaceutics.

[25]  Anatol Jaworek,et al.  Micro- and nanoparticle production by electrospraying , 2007 .

[26]  A. T. Sobczyk,et al.  Electrospraying route to nanotechnology: An overview , 2008 .

[27]  B. Kojić-Prodić,et al.  Structure of the anti‐inflammatory drug 4‐hydroxy‐2‐methyl‐N‐2‐pyridyl‐2H‐1λ6,2‐benzothiazine‐3‐carboxamide 1,1‐dioxide (piroxicam) , 1982 .

[28]  J. Lubach,et al.  Mechanochromism of piroxicam accompanied by intermolecular proton transfer probed by spectroscopic methods and solid-phase changes. , 2005, Journal of the American Chemical Society.

[29]  P. Taddei,et al.  Raman and solid state 13C-NMR investigation of the structure of the 1 : 1 amorphous piroxicam : beta-cyclodextrin inclusion compound. , 1999, Biospectroscopy.

[30]  G. Reck,et al.  Prediction and establihement of a new crystalline pyroxicam modification , 1990 .

[31]  J. Richards,et al.  Piroxicam monohydrate: a zwitterionic form, C15H13N3O4S.H2O , 1984 .

[32]  J. M. Grace,et al.  A review of liquid atomization by electrical means , 1994 .

[33]  I. Kikic,et al.  Piroxicam solid state studies after processing with SAS technique , 2010 .

[34]  H. Chakraborty,et al.  Photophysical studies of oxicam group of NSAIDs: piroxicam, meloxicam and tenoxicam. , 2003, Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy.

[35]  E. Whipple,et al.  Zwitterionic piroxicam in polar solution , 1989 .

[36]  G. Angioni,et al.  Nanocrystals as tool to improve piroxicam dissolution rate in novel orally disintegrating tablets. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[37]  S. Bates,et al.  Polymorphism in Piroxicam , 2004 .

[38]  M. Nyström,et al.  Fabrication of amorphous pharmaceutical materials by electrospraying into reduced pressure , 2011 .

[39]  Hyunbong Choi,et al.  Solvent Dependence of Absorption and Fluorescence Spectra of Piroxicam. A Possible Intramolecular Proton Transfer in the Excited State , 1989 .